Please login to the form below

Not currently logged in
Email:
Password:

Cephalon posts record sales

Biopharmaceutical company reports strong second-quarter figures

Cephalon has reported a second-quarter sales increase of 11 per cent to $539m from $485m in Q2 2008, exceeding sales guidance for the period. Adjusted income for the quarter was $110.7m, up 31 per cent on the 2008 second-quarter figure of $84.5m.

The company's figures were bolstered by a strong performance in its oncology franchise where sales increased 86 per cent to $82.2m – figures for Treanda for the treatment of indolent B-cell non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) totalled $55.8m. Sales at Cephalon's central nervous system franchise were also strong rising 16 per cent to $290.6m. In the company's pain division sales fell 8 per cent to $123.6m with growing sales of Amrix largely offsetting the continued generic erosion of Actiq.

The quarter also saw Cephalon launch Nuvigil tablets and file a supplemental new drug application with the US Food and Drug Administration (FDA) for the drug as a treatment for excessive sleepiness associated with jet lag. If Nuvigil is approved it will be the first acute indication for the franchise.

"Nuvigil is off to a great start and in order to serve additional patients we continue to make meaningful progress with our clinical programmes to further develop this product," said Dr Frank Baldino Jr, Cephalon chairman and CEO. "In addition, Treanda and Amrix continue to experience tremendous year-on-year growth. We plan to continue to execute upon our strategy of diversification through our internal discovery and business development activities while delivering solid financial performance," he added.

Cephalon acquired a controlling interest in Australian biotech firm Arana Therapeutics in the second quarter as it continued to build its biotechnology platform. Under the terms of the deal, Cephalon has access to Arana's antibody humanisation and optimisation technology as well as a pipeline of biologics for inflammatory diseases and cancer. 

5th August 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles

With a network of more than 27,000 employees conducting business in approximately 100 countries, we have helped develop or commercialize...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics